ABBV stock forecast, quote, news & analysis

Key Takeaways

• AbbVie shares traded at approximately $259.36 as of the latest close, reflecting a modest gain of about 2.4% over the trailing 30-day period, with the stock recovering from a mid-July dip that briefly pushed prices near $244.
• The company lowered its Q2 2026 adjusted EPS guidance to $3.57–$3.61 and full-year 2026 adjusted EPS to $13.91–$14.11, incorporating a $291 million acquired IPR&D and milestone expense, which temporarily weighed on sentiment.
• Multiple Wall Street analysts raised price targets in July, including BMO Capital Markets ($300), Canaccord Genuity ($282), and Bank of America ($276), reflecting continued confidence in the immunology and neuroscience franchises.
• Pipeline developments dominated recent headlines: the European Commission approved Tepkinly for follicular lymphoma, while the Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its primary endpoint, creating mixed signals for AbbVie's oncology ambitions.
• Q2 2026 earnings are scheduled for July 31, with investors focused on Skyrizi and Rinvoq sales trajectory as the key barometer of AbbVie's post-Humira growth story.

Current Market Snapshot

AbbVie Inc. (ABBV) closed near $259.36 in the most recent trading session, hovering just below its 52-week high of $261.64. The stock's 50-day moving average sits at approximately $234.57 and its 200-day moving average at roughly $222.88, indicating a sustained uptrend across multiple timeframes. With a market capitalization of roughly $458 billion, AbbVie remains one of the largest pure-play biopharmaceutical companies listed on the NYSE. Institutional ownership stands at approximately 70.23%, underscoring deep conviction among professional money managers. The company's low beta of 0.30 reflects its defensive characteristics within the healthcare sector, though upcoming catalysts — particularly the July 31 earnings release — could introduce near-term volatility.

AbbVie (ABBV) Business Overview and Competitive Position

AbbVie is a global, research-driven biopharmaceutical company spun off from Abbott Laboratories (ABT) in 2013 and headquartered in North Chicago, Illinois. The company discovers, develops, and commercializes advanced therapies across immunology, oncology, neuroscience, and other therapeutic areas. Its flagship immunology franchise — anchored by Skyrizi and Rinvoq — has successfully offset much of the revenue erosion from Humira's U.S. biosimilar competition, with Skyrizi generating $4.5 billion in Q1 2026 alone. The neuroscience portfolio, led by Vraylar, Ubrelvy, Qulipta, and Vyalev, delivered nearly $2.9 billion in Q1 revenue. AbbVie's pipeline spans over 90 compounds in development, and its commitment to returning capital to shareholders is evidenced by a quarterly dividend of $1.73 per share, representing an annualized yield of approximately 2.7%.

Recent Developments Driving ABBV

Several developments shaped AbbVie's trajectory in recent weeks. On July 6, the company filed an 8-K with the SEC disclosing $291 million in acquired IPR&D and milestone expenses for Q2, translating to a $0.17 headwind on both GAAP and adjusted EPS. As a result, full-year 2026 adjusted EPS guidance now stands at $13.91 to $14.11 — below the prior Street consensus of approximately $14.25. This triggered a brief sell-off that pushed shares to an intra-month low near $244 before buyers stepped in.

On the analyst front, multiple firms reaffirmed bullish stances. BMO Capital Markets raised its target to $300, Canaccord Genuity lifted its target to $282, and Bank of America moved to $276 — all with Buy or Outperform ratings. Guggenheim also raised its target to $261, citing confidence in Rinvoq's growth trajectory and the Epkinly opportunity in first-line diffuse large B-cell lymphoma.

Pipeline news presented a mixed picture. The European Commission granted marketing authorization for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, expanding AbbVie's oncology footprint in Europe. Conversely, the Phase 3 EPCORE DLBCL-1 trial — co-developed with Genmab (GMAB) — failed to meet its sole U.S. primary endpoint, a setback for the lymphoma franchise. Additionally, AbbVie completed its acquisition of a device manufacturing facility in Tempe, Arizona, from West Pharmaceutical Services (WST) on July 1, strengthening its manufacturing capacity for immunology and neuroscience injectables.

Trending AI Robots

For investors seeking data-driven insights beyond traditional analysis, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots actively monitoring thousands of tickers across global markets. Tickeron hosts hundreds of algorithmic trading bots, each employing distinct strategies, timeframes, and performance metrics. The Trending AI Robots section highlights only the top-performing and most contextually relevant bots, helping traders identify actionable opportunities across various market conditions. Whether you favor short-term momentum strategies or longer-duration swing trades, this resource provides a window into how AI is reshaping modern trading. Explore the curated selection to see which strategies are resonating in the current market environment.

2026 Outlook and What Investors Should Watch

AbbVie's Q2 2026 earnings report on July 31 represents the most immediate catalyst. Consensus estimates point to Skyrizi sales of approximately $5.49 billion and Rinvoq sales near $2.47 billion. The pace at which these two drugs continue capturing market share in inflammatory bowel disease and other indications will be critical in determining whether AbbVie can maintain double-digit revenue growth. The pending $10.9 billion acquisition of Apogee — expected to close later this quarter — will add a new dimension to AbbVie's immunology pipeline, though integration costs and deal-related uncertainties bear watching. On the regulatory front, investors should monitor potential U.S. approval for tavapadon in Parkinson's disease and the ongoing label expansion efforts for Rinvoq in alopecia areata and non-segmental vitiligo. Macroeconomic factors, including potential drug pricing legislation and interest rate developments, remain relevant for a stock that carries significant weight in both growth and income-oriented portfolios.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations